Developed by Veloxis through Phase II in the U.S., AtorFen demonstrated improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with Lipitor (atorvastatin, Pfizer Inc.) alone, as well as a significantly greater effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with Tricor (fenofibrate, Abbott) alone

Developed by Veloxis through Phase II in the U.S., AtorFen demonstrated improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with Lipitor (atorvastatin, Pfizer Inc.) alone, as well as a significantly greater effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with Tricor (fenofibrate, Abbott) alone

Antares Pharma Inc., of Ewing, N.J., has licensed to Pfizer Inc.'s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America...Pfizer Inc., of New York, said the FDA accepted for review its new drug application seeking approval of oral JAK inhibitor tofacitinib for moderate to severe active rheumatoid arthritis

Phylogica Ltd., of Perth, Australia, said it completed the first stage of its collaboration with New York-based Pfizer Inc., triggering an undisclosed milestone payment

plc and Madison-N.J.-based Wyeth (now part of Pfizer Inc.), which are co-developing bapineuzumab, a Phase III-stage Alzheimer's disease candidate...Phylogica Ltd., of Perth, Australia, said it completed the first stage of its collaboration with New York-based Pfizer Inc., triggering an undisclosed milestone payment

Cellzome will use its Episphere technology in collaboration with Neusentis, a Cambridge, UK, subsidiary of New York-based Pfizer Inc., the University of Sheffield and Plasticell Ltd., of London, to identify protein fingerprints that predict potentially harmful changes in the stem cells

Cellzome will use its Episphere technology in collaboration with Neusentis, a Cambridge, UK, subsidiary of New York-based Pfizer Inc., the University of Sheffield and Plasticell Ltd., of London, to identify protein fingerprints that predict potentially harmful changes in the stem cells

Pfizer Inc., of New York, said it completed the acquisition of privately held Excaliard Pharmaceuticals Inc., of San Diego, gaining rights to drugs for treating skin scarring

and Pfizer Inc., both of New York, said the FDA accepted for review a new drug application for the Factor Xa inhibitor Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation

Pfizer Inc., of New York, requested that the FDA withdraw approval of acute myeloid leukemia (AML) drug Mylotarg (gemtuzumab ozogamicin), and the agency has done so

Pfizer Inc., of New York, said the European Medicines Agency validated and began review of the company's tofacitinib, an oral JAK inhibitor, for moderate to severe active rheumatoid arthritis

Pfizer Inc., of New York, said the European Commission approved Vyndaqel (tafamidis) to treat transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with Stage I symptomatic polyneuropathy

A Phase I/II study in 36 patients conducted prior to firm's 2009 acquisition of rights to the product from New York-based Pfizer Inc

Pfizer Inc., of New York completed its acquisition of Icagen Inc., of Durham, N.C. The transaction, first announced in July, had an aggregate value, including the value of approximately 11 percent of Icagen's stock already owned by Pfizer, of about $56 million

DeCode Genetics Inc., of Reykjavik, Iceland, said it inked a research collaboration with Pfizer Inc., of New York, to discover sequence variants associated with specific clinical phenotypes related to systemic lupus erythematosus...DiaGenic ASA, of Oslo, Norway, reported preliminary findings from an R&D collaboration with New York-based Pfizer Inc

Acura Pharmaceuticals Inc., of Palatine, Ill., said partner New York-based Pfizer Inc

DiaGenic ASA, of Oslo, Norway, reported preliminary findings from an R&D collaboration with New York-based Pfizer Inc

DeCode Genetics Inc., of Reykjavik, Iceland, said it inked a research collaboration with Pfizer Inc., of New York, to discover sequence variants associated with specific clinical phenotypes related to systemic lupus erythematosus

Exonhit SA, of Paris, entered a research agreement with Pfizer Inc., of New York, for the identification of new Alzheimer's disease biomarkers using Exonhit's Genome-Wide SpliceArray platform